The purchase will add key geographies and services to Biorasi’s offerings as ABR provides Phase II to IV clinical research project management, monitoring, and regulatory outsourcing for its sponsors in the region.
Boris Reznik, Chairman of Biorasi, told Outsourcing-Pharma.com: “Biorasi has been fortunate not to need to acquire backlog, we have been growing fast while relying on our internal bookings capabilities. We have done a couple of acquisitions for the purposes of enhancing our resources in specific areas of the world. ABR acquisition is specifically focused on enhancing our presence in Western Europe.”
Tigran Arzumanov, ABR Principle, added that his company has been working with Biorasi “for over a year and have been extremely impressed with the superiority of Biorasi's innovative clinical research project delivery model.”
Biorasi has been running world-wide clinical trials for over a decade, with a presence in North and South America, Eastern Europe and Asia. Biorasi also has strength in Russia and Ukraine, and a decade-long established presence in Czech Republic, Poland, Serbia, Latvia, and United Kingdom.
The addition of ABR's regional base will create a strong footprint throughout Europe, Reznick said.
The ARB acquisition also follows Biorasi’s acquisition of Ukrainian CRO Sponsors Clinical Research Group, which followed a long-standing collaboration between the two companies.
“Most of the trials we run are pivotal trials that require global approach,” Reznick said. “Our prior acquisition of a CRO in Ukraine has worked our very well. We are confident that the addition of ABR will have even greater positive impact.”